1.Burden and Trends of Ulcerative Colitis in China and Worldwide
Weiqing ZHANG ; Yizhong LIANG ; Meilan MO ; Zhulin WU ; Weijun LUO ; Dong ZHANG ; Derong LIN
Journal of Sun Yat-sen University(Medical Sciences) 2026;47(5):857-867
ObjectiveTo assess changes in the incidence, prevalence, and disability-adjusted life-year (DALY) burden of ulcerative colitis (UC) in China and worldwide from 1990 to 2023 using data from the Global Burden of Disease Study 2023 (GBD 2023), and to examine demographic drivers and future trends. MethodsUC data for China, the world, and 204 countries and territories were extracted from the GBD 2023 Results Tool. Age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized DALY rate (ASDR), with 95% uncertainty interval (UI), were obtained. Joinpoint regression was used to estimate average annual percent change (AAPC) and 95% confidence interval (CI). Spearman rank correlation, inequality and frontier analyses, Das Gupta decomposition, and autoregressive integrated moving average (ARIMA) models were used to assess associations with the sociodemographic index (SDI), cross-country burden disparities, demographic drivers, and trends from 2024 to 2035, respectively. ResultsIn 2023, the ASIR, ASPR, and ASDR in China were 0.94, 5.95, and 5.94 per 100 000 population, respectively, lower than the corresponding global estimates of 2.87, 28.48, and 13.82 per 100 000 population. From 1990 to 2023, China’s ASIR and ASPR increased, with AAPCs of 2.720% (95% CI: 2.133%-3.309%) and 2.261% (95% CI: 1.617%-2.908%), whereas the ASDR decreased (AAPC=-3.056%, 95% CI: -3.449% to -2.662%). Globally, ASIR increased slightly, whereas ASPR and ASDR decreased. In China, the crude incidence, prevalence, and DALY rates peaked at ages 50-54 years, 60-64 years, and ≥95 years, respectively. ASIR and ASPR were positively correlated with SDI (rs=0.5794 and 0.6177, both P<0.001), whereas the correlation between ASDR and SDI was not statistically significant (rs=0.0666, P=0.343). In China, epidemiological change contributed most to increases in incident and prevalent cases, and changes in age-specific rates contributed most to the decline in DALYs; globally, population growth and population aging contributed most to the increase in DALYs. By 2035, China’s ASIR, ASPR, and ASDR were projected to be 1.23, 6.37, and 2.55 per 100 000 population, respectively. ConclusionsFrom 1990 to 2023, the age-standardized incidence and prevalence rates of UC increased in China, whereas the age-standardized DALY rate decreased, and peaks in absolute burden generally shifted toward middle-aged and older age groups. The projected directions may persist. These findings may provide reference for long-term UC management and health-resource planning.
2.Burden and Trends of Ulcerative Colitis in China and Worldwide
Weiqing ZHANG ; Yizhong LIANG ; Meilan MO ; Zhulin WU ; Weijun LUO ; Dong ZHANG ; Derong LIN
Journal of Sun Yat-sen University(Medical Sciences) 2026;47(5):857-867
ObjectiveTo assess changes in the incidence, prevalence, and disability-adjusted life-year (DALY) burden of ulcerative colitis (UC) in China and worldwide from 1990 to 2023 using data from the Global Burden of Disease Study 2023 (GBD 2023), and to examine demographic drivers and future trends. MethodsUC data for China, the world, and 204 countries and territories were extracted from the GBD 2023 Results Tool. Age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized DALY rate (ASDR), with 95% uncertainty interval (UI), were obtained. Joinpoint regression was used to estimate average annual percent change (AAPC) and 95% confidence interval (CI). Spearman rank correlation, inequality and frontier analyses, Das Gupta decomposition, and autoregressive integrated moving average (ARIMA) models were used to assess associations with the sociodemographic index (SDI), cross-country burden disparities, demographic drivers, and trends from 2024 to 2035, respectively. ResultsIn 2023, the ASIR, ASPR, and ASDR in China were 0.94, 5.95, and 5.94 per 100 000 population, respectively, lower than the corresponding global estimates of 2.87, 28.48, and 13.82 per 100 000 population. From 1990 to 2023, China’s ASIR and ASPR increased, with AAPCs of 2.720% (95% CI: 2.133%-3.309%) and 2.261% (95% CI: 1.617%-2.908%), whereas the ASDR decreased (AAPC=-3.056%, 95% CI: -3.449% to -2.662%). Globally, ASIR increased slightly, whereas ASPR and ASDR decreased. In China, the crude incidence, prevalence, and DALY rates peaked at ages 50-54 years, 60-64 years, and ≥95 years, respectively. ASIR and ASPR were positively correlated with SDI (rs=0.5794 and 0.6177, both P<0.001), whereas the correlation between ASDR and SDI was not statistically significant (rs=0.0666, P=0.343). In China, epidemiological change contributed most to increases in incident and prevalent cases, and changes in age-specific rates contributed most to the decline in DALYs; globally, population growth and population aging contributed most to the increase in DALYs. By 2035, China’s ASIR, ASPR, and ASDR were projected to be 1.23, 6.37, and 2.55 per 100 000 population, respectively. ConclusionsFrom 1990 to 2023, the age-standardized incidence and prevalence rates of UC increased in China, whereas the age-standardized DALY rate decreased, and peaks in absolute burden generally shifted toward middle-aged and older age groups. The projected directions may persist. These findings may provide reference for long-term UC management and health-resource planning.
3.Analysis of association between infection with SARS-CoV-2 Omicron variant during pregnancy and common illnesses of infants
Weiqing XU ; Dan LUO ; Hong JIANG ; Junyao SHI
Shanghai Journal of Preventive Medicine 2025;37(1):34-38
ObjectiveTo investigate the association between maternal infection with the SARS-CoV-2 Omicron variant during pregnancy and common infant illnesses and neurodevelopment. MethodsA cohort study was designed, selecting 113 pregnant women from Shanghai’s Pudong New Area who tested positive for SARS-CoV-2 by nasal swab reverse transcription-polymerase chain reaction (RT-PCR) and were transported to medical institutions for isolation treatment between March and May 2022. These women constituted the pregnancy infection group. Concurrently, 226 pregnant women from the same region and time period who did not infect with SARS-CoV-2 were selected as the control group. Both groups were followed up until delivery and their offspring’s one year old. The differences in the risk of common infant illnesses and the level of infant’s neurodevelopment at age one were compared between the two groups. ResultsNo significant difference was found in the incidence of common illnesses before one year of age between the pregnancy infection group and the control group. Additionally, no significant differences were found in any domain scores of the ASQ-3 between the two groups. ConclusionMaternal infection with SARS-CoV-2 Omicron variant during pregnancy was not statistically significant correlated with common infant illnesses in infancy and neurodevelopment at age one.
4.Study on the Mechanism of the Intervention of Yiqi Jianpi Jiedu Compound on HBx-Mediated Liver Cancer Stem Cells from the Perspective of PI3K/AKT Pathway
Zhulin WU ; Sen LIN ; Weijun LUO ; Siyi LI ; Weiqing ZHANG ; Lanyue MA ; Chunshan WEI ; Lisheng PENG
World Science and Technology-Modernization of Traditional Chinese Medicine 2025;27(4):939-949
Objective To explore the mechanism of the intervention effect of Qizhu Xiaozheng Fang(QZXZF),a representative prescription of Yiqi Jianpi Jiedu(replenishing qi,strengthening spleen,and removing toxicity),in treating HBx-mediated liver cancer stem cells(LCSCs).Methods The Kaplan-Meier survival analysis was used to investigate the effects of Yiqi Jianpi Jiedu on the prognosis of patients with HBV-HCC.The network pharmacology method was utilized to predict the targets and pathways of QZXZF in treating HBx-related LCSCs(HBx-LCSCs).HBx-LCSCs cells were screened by stably transfecting HBx and serum-free culture.The therapeutic effect of QZXZF on HBx-LCSCs was tested in vitro,and its effect on stemness markers and PI3K/Akt pathway was verified by qRT-PCR and Western blot.Results Yiqi Jianpi Jiedu could improve the overall survival time of HBV-HCC patients.Combined with the results of network pharmacology,the mechanism of action of QZXZF against HBx-LCSCs was explored from the PI3K/Akt pathway.Compared with the blank vector group,HBx can promote the expression of stemness markers in HBx-LCSCs cells;compared with the HBx-LCSCs control group,QZXZF could significantly inhibit the proliferation and colony formation of HBx-LCSCs cells(in a concentration-dependent manner),and could reduce the expression of stemness markers(EpCAM,NANOG,SOX2,and OCT4),phosphorylated PI3K(p-PI3K)and phosphorylated AKT(p-AKT)proteins.Conclusion QZXZF may regulate HBx-mediated LCSCs through PI3K/AKT pathways,providing a reference for the mechanism of TCM intervention in LCSCs.
5.Gallstones, cholecystectomy, and cancer risk: an observational and Mendelian randomization study.
Yuanyue ZHU ; Linhui SHEN ; Yanan HUO ; Qin WAN ; Yingfen QIN ; Ruying HU ; Lixin SHI ; Qing SU ; Xuefeng YU ; Li YAN ; Guijun QIN ; Xulei TANG ; Gang CHEN ; Yu XU ; Tiange WANG ; Zhiyun ZHAO ; Zhengnan GAO ; Guixia WANG ; Feixia SHEN ; Xuejiang GU ; Zuojie LUO ; Li CHEN ; Qiang LI ; Zhen YE ; Yinfei ZHANG ; Chao LIU ; Youmin WANG ; Shengli WU ; Tao YANG ; Huacong DENG ; Lulu CHEN ; Tianshu ZENG ; Jiajun ZHAO ; Yiming MU ; Weiqing WANG ; Guang NING ; Jieli LU ; Min XU ; Yufang BI ; Weiguo HU
Frontiers of Medicine 2025;19(1):79-89
This study aimed to comprehensively examine the association of gallstones, cholecystectomy, and cancer risk. Multivariable logistic regressions were performed to estimate the observational associations of gallstones and cholecystectomy with cancer risk, using data from a nationwide cohort involving 239 799 participants. General and gender-specific two-sample Mendelian randomization (MR) analysis was further conducted to assess the causalities of the observed associations. Observationally, a history of gallstones without cholecystectomy was associated with a high risk of stomach cancer (adjusted odds ratio (aOR)=2.54, 95% confidence interval (CI) 1.50-4.28), liver and bile duct cancer (aOR=2.46, 95% CI 1.17-5.16), kidney cancer (aOR=2.04, 95% CI 1.05-3.94), and bladder cancer (aOR=2.23, 95% CI 1.01-5.13) in the general population, as well as cervical cancer (aOR=1.69, 95% CI 1.12-2.56) in women. Moreover, cholecystectomy was associated with high odds of stomach cancer (aOR=2.41, 95% CI 1.29-4.49), colorectal cancer (aOR=1.83, 95% CI 1.18-2.85), and cancer of liver and bile duct (aOR=2.58, 95% CI 1.11-6.02). MR analysis only supported the causal effect of gallstones on stomach, liver and bile duct, kidney, and bladder cancer. This study added evidence to the causal effect of gallstones on stomach, liver and bile duct, kidney, and bladder cancer, highlighting the importance of cancer screening in individuals with gallstones.
Humans
;
Mendelian Randomization Analysis
;
Gallstones/complications*
;
Female
;
Male
;
Cholecystectomy/statistics & numerical data*
;
Middle Aged
;
Risk Factors
;
Aged
;
Adult
;
Neoplasms/etiology*
;
Stomach Neoplasms/epidemiology*
6.Human Digital Metabolic Chamber Platform: Construction Standards and Testing Specifications
Weiqing WANG ; Shijia PAN ; Yixiang HU ; Yashu ZHU ; Riqiang BAO ; Guang NING ; Yifei ZHANG ; Lifeng ZHU ; Xiaoxia LUO ; Jiqiu WANG ; Zhuoran ZHANG ; Shi XIANG
Chinese Journal of Endocrinology and Metabolism 2025;41(12):1-16
This document targets digital human metabolic chamber platforms and specifies construction standards and testing protocols covering the full lifecycle of " build-test-operate." It encompasses chamber engineering and environmental control, digital platform and cybersecurity architecture, metabolic measurement and multimodal data acquisition, as well as quantitative system performance and data quality indicators with verifiable acceptance tests. By standardizing architecture, interfaces, and quality control, the specification enables multicenter data interoperability and harmonized quality management, providing high-quality, verifiable, and traceable infrastructure to support precision metabolism research and clinical translation in China.
7.Study on the Mechanism of the Intervention of Yiqi Jianpi Jiedu Compound on HBx-Mediated Liver Cancer Stem Cells from the Perspective of PI3K/AKT Pathway
Zhulin WU ; Sen LIN ; Weijun LUO ; Siyi LI ; Weiqing ZHANG ; Lanyue MA ; Chunshan WEI ; Lisheng PENG
World Science and Technology-Modernization of Traditional Chinese Medicine 2025;27(4):939-949
Objective To explore the mechanism of the intervention effect of Qizhu Xiaozheng Fang(QZXZF),a representative prescription of Yiqi Jianpi Jiedu(replenishing qi,strengthening spleen,and removing toxicity),in treating HBx-mediated liver cancer stem cells(LCSCs).Methods The Kaplan-Meier survival analysis was used to investigate the effects of Yiqi Jianpi Jiedu on the prognosis of patients with HBV-HCC.The network pharmacology method was utilized to predict the targets and pathways of QZXZF in treating HBx-related LCSCs(HBx-LCSCs).HBx-LCSCs cells were screened by stably transfecting HBx and serum-free culture.The therapeutic effect of QZXZF on HBx-LCSCs was tested in vitro,and its effect on stemness markers and PI3K/Akt pathway was verified by qRT-PCR and Western blot.Results Yiqi Jianpi Jiedu could improve the overall survival time of HBV-HCC patients.Combined with the results of network pharmacology,the mechanism of action of QZXZF against HBx-LCSCs was explored from the PI3K/Akt pathway.Compared with the blank vector group,HBx can promote the expression of stemness markers in HBx-LCSCs cells;compared with the HBx-LCSCs control group,QZXZF could significantly inhibit the proliferation and colony formation of HBx-LCSCs cells(in a concentration-dependent manner),and could reduce the expression of stemness markers(EpCAM,NANOG,SOX2,and OCT4),phosphorylated PI3K(p-PI3K)and phosphorylated AKT(p-AKT)proteins.Conclusion QZXZF may regulate HBx-mediated LCSCs through PI3K/AKT pathways,providing a reference for the mechanism of TCM intervention in LCSCs.
8.Human Digital Metabolic Chamber Platform: Construction Standards and Testing Specifications
Weiqing WANG ; Shijia PAN ; Yixiang HU ; Yashu ZHU ; Riqiang BAO ; Guang NING ; Yifei ZHANG ; Lifeng ZHU ; Xiaoxia LUO ; Jiqiu WANG ; Zhuoran ZHANG ; Shi XIANG
Chinese Journal of Endocrinology and Metabolism 2025;41(12):1-16
This document targets digital human metabolic chamber platforms and specifies construction standards and testing protocols covering the full lifecycle of " build-test-operate." It encompasses chamber engineering and environmental control, digital platform and cybersecurity architecture, metabolic measurement and multimodal data acquisition, as well as quantitative system performance and data quality indicators with verifiable acceptance tests. By standardizing architecture, interfaces, and quality control, the specification enables multicenter data interoperability and harmonized quality management, providing high-quality, verifiable, and traceable infrastructure to support precision metabolism research and clinical translation in China.
9.The Association between Educational Attainment and the Risk of Nonalcoholic Fatty Liver Disease among Chinese Adults: Findings from the REACTION Study
Yuanyue ZHU ; Long WANG ; Lin LIN ; Yanan HUO ; Qin WAN ; Yingfen QIN ; Ruying HU ; Lixin SHI ; Qing SU ; Xuefeng YU ; Li YAN ; Guijun QIN ; Xulei TANG ; Gang CHEN ; Shuangyuan WANG ; Hong LIN ; Xueyan WU ; Chunyan HU ; Mian LI ; Min XU ; Yu XU ; Tiange WANG ; Zhiyun ZHAO ; Zhengnan GAO ; Guixia WANG ; Feixia SHEN ; Xuejiang GU ; Zuojie LUO ; Li CHEN ; Qiang LI ; Zhen YE ; Yinfei ZHANG ; Chao LIU ; Youmin WANG ; Shengli WU ; Tao YANG ; Huacong DENG ; Lulu CHEN ; Tianshu ZENG ; Jiajun ZHAO ; Yiming MU ; Weiqing WANG ; Guang NING ; Yufang BI ; Yuhong CHEN ; Jieli LU
Gut and Liver 2024;18(4):719-728
Background/Aims:
Low educational attainment is a well-established risk factor for nonalcoholic fatty liver disease (NAFLD) in developed areas. However, the association between educational attainment and the risk of NAFLD is less clear in China.
Methods:
A cross-sectional study including over 200,000 Chinese adults across mainland China was conducted. Information on education level and lifestyle factors were obtained through standard questionnaires, while NAFLD and advanced fibrosis were diagnosed using validated formulas. Outcomes included the risk of NAFLD in the general population and high probability of fibrosis among patients with NAFLD. Logistic regression analysis was employed to estimate the risk of NAFLD and fibrosis across education levels. A causal mediation model was used to explore the potential mediators.
Results:
Comparing with those receiving primary school education, the multi-adjusted odds ratios (95% confidence intervals) for NAFLD were 1.28 (1.16 to 1.41) for men and 0.94 (0.89 to 0.99) for women with college education after accounting for body mass index. When considering waist circumference, the odds ratios (95% CIs) were 0.94 (0.86 to 1.04) for men and 0.88 (0.80 to 0.97) for women, respectively. The proportions mediated by general and central obesity were 51.00% and 68.04% for men, while for women the proportions were 48.58% and 32.58%, respectively. Furthermore, NAFLD patients with lower educational attainment showed an incremental increased risk of advanced fibrosis in both genders.
Conclusions
In China, a low education level was associated with a higher risk of prevalent NAFLD in women, as well as high probability of fibrosis in both genders.
10.Corrigendum to: The Association between Educational Attainment and the Risk of Nonalcoholic Fatty Liver Disease among Chinese Adults: Findings from the REACTION Study
Yuanyue ZHU ; Long WANG ; Lin LIN ; Yanan HUO ; Qin WAN ; Yingfen QIN ; Ruying HU ; Lixin SHI ; Qing SU ; Xuefeng YU ; Li YAN ; Guijun QIN ; Xulei TANG ; Gang CHEN ; Shuangyuan WANG ; Hong LIN ; Xueyan WU ; Chunyan HU ; Mian LI ; Min XU ; Yu XU ; Tiange WANG ; Zhiyun ZHAO ; Zhengnan GAO ; Guixia WANG ; Feixia SHEN ; Xuejiang GU ; Zuojie LUO ; Li CHEN ; Qiang LI ; Zhen YE ; Yinfei ZHANG ; Chao LIU ; Youmin WANG ; Shengli WU ; Tao YANG ; Huacong DENG ; Lulu CHEN ; Tianshu ZENG ; Jiajun ZHAO ; Yiming MU ; Weiqing WANG ; Guang NING ; Yufang BI ; Yuhong CHEN ; Jieli LU
Gut and Liver 2024;18(5):926-927

Result Analysis
Print
Save
E-mail